DVA — DaVita Inc.

DaVita (DVA) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted Operating Income: $482 million, exceeding forecasts by approximately $50 million.
• Adjusted EPS: $2.87, with guidance raised to $14.10 - $15.20 per share for the year.
• Free Cash Flow: $140 million, guidance remains unchanged due to variability.
• Treatment Volume: Slightly above forecast; full-year growth expectations raised from flat to 25-50 basis points.
• Revenue per Treatment (RPT): Declined by $5 sequentially but showed a year-over-year growth of approximately 4%. Full-year growth expected at 1-2%.
• Patient Care Cost per Treatment: Flat compared to Q4, with lower-than-expected costs due to productivity improvements.

2. Strategic Updates and Business Highlights

• Integrated Kidney Care (IKC): Continued momentum with improvements in CMS metrics, achieving the highest aggregate savings in the CKCC program.
• Technology Investments: Focus on enhancing IT systems and deploying AI solutions to improve operational efficiency and clinical outcomes.
• Market Positioning: Actively capturing market share from competitors, particularly due to clinic closures by Fresenius, with expectations for patient transfers to contribute positively to treatment growth.

3. Forward Guidance and Outlook

• Adjusted Operating Income Guidance: Raised to $2.15 billion - $2.25 billion, primarily driven by higher treatment volume and lower patient care costs.
• Volume Growth Expectations: Increased to 25-50 basis points for the year, with expectations for treatment per normalized day growth to reach 50-75 basis points.
• RPT Guidance: Maintained at 1-2% growth for the year, despite Q1's strong performance.

4. Bad News, Challenges, or Points of Concern

• ACA Impact: Although ACA enrollment is trending better than expected, the mix of patients selecting lower-level plans could lead to higher out-of-pocket costs and a modest RPT headwind.
• Competitive Pressures: Ongoing clinic closures by competitors may impact patient retention and market dynamics.
• G&A Costs: Increased by 13% year-over-year due to technology investments, raising concerns about cost management relative to revenue growth.

5. Notable Q&A Insights

• Volume Dynamics: Weather and flu season impacts were in line with forecasts, with better-than-expected mortality contributing to volume growth.
• RPT Variability: The strong RPT in Q1 was partly due to timing effects; however, the company expects to maintain its annual guidance despite fluctuations.
• Market Share Capture: DaVita is focused on leveraging clinic closures by competitors to attract new patients, although the extent of this impact remains uncertain.
• Technology Investments: Long-term benefits are anticipated from technology initiatives, though the immediate impact on operating performance is still being assessed.

Overall, DaVita reported a strong start to 2026 with improved financial metrics and strategic initiatives aimed at enhancing clinical outcomes and operational efficiency, while navigating challenges related to market competition and ACA impacts.